Minted: - / 5000

4250 Drinabant
2d9f7b49e846740409d764532197dfa288db5d8f0b46f1f0d0c82a390ab17484

Properties

Background

Blue
Bottle

Light blue
Cap

Green
Syringe

Purple
Bubbles
No
Drops
No
Label
Cross

Chemistry

Formula
C23H20Cl2F2N2O2S
Carbon
23
Polarity
Neutral

Drinabant (INN; AVE-1625) is a drug that acts as a selective CB₁ receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB₁ antagonist that was also under development by Sanofi-Aventis.

From Wikipedia, the free encyclopedia. License: CC BY-SA.